Vir Biotechnology Inc. (NASDAQ: VIR) reported Q4 EPS of ($0.31), $0.23 better than the analyst estimate of ($0.54). Revenue for the quarter came in at $64.07 million versus the consensus estimate of $1.42 million.

For earnings history and earnings-related data on Vir Biotechnology Inc. (VIR) click here.